@Gussington did generalise: pre commercialisation, where revenue is less than expenses such as R&D and the like, is always going to be a slow increase in market cap relative to the share price.
Correction: ... is sometimes going to be a slow increase in market cap ...
And sometimes a complete duster, which becomes worthless.
I'm not a particularly insightful investor / stock-watcher, but I can only conclude that in Biotech especially, stocks with merit far outnumber stocks which reach success.
I'm holding a modest parcel, and I've buying in and selling out of this company for years. Not now or ever would I consider it a safe bet, of even avoiding a crash to 25% of current valuation.
Is it worth the risk ...?
Oh, yeah ... sort of. If you like risk.
I don't mind jumping in where fools fear to tread.
In other words, invest in it if you can afford to lose it.
- Forums
- ASX - By Stock
- AVR
- TAVR MARKET Superiority
TAVR MARKET Superiority, page-78
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.30 |
Change
0.150(0.99%) |
Mkt cap ! $294.1M |
Open | High | Low | Value | Volume |
$15.35 | $15.35 | $15.00 | $92.29K | 6.09K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50 | $15.20 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.30 | 276 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50 | 15.200 |
1 | 39 | 15.040 |
1 | 1000 | 15.000 |
1 | 756 | 14.950 |
1 | 300 | 14.900 |
Price($) | Vol. | No. |
---|---|---|
15.300 | 276 | 1 |
15.700 | 277 | 1 |
15.880 | 250 | 1 |
16.000 | 100 | 1 |
16.030 | 999 | 1 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online